drugset / Trial / NCT00450138

Open Label, Phase I ZD6474 Head and Neck Cancer Study

NCT00450138

Phase 1 Completed 48 enrolled Sanofi
Non-randomizedParallel-groupOpen-labelTreatment

Summary

The purpose of this study is to determine the maximum tolerated dose of ZD6474 given in combination with radiation or in combination with chemotherapy and radiation in patients with squamous cell carcinoma of the head and neck.

Timeline

Start
2006-12
Primary completion
2009-11
Completion
2011-11

Drugs

EvaluationDrugModalityDoseRoute
Subject Vandetanib Small molecule Oral
Background Cisplatin Other / unclassified Intravenous

Indications